{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T07:06:50Z","timestamp":1789110410084,"version":"build-2803163510"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clinic Rev Allerg Immunol"],"DOI":"10.1007\/s12016-026-09181-3","type":"journal-article","created":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T06:32:24Z","timestamp":1789108344000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeting IL-33 and TSLP: A Novel Approach to Modulate Type 2 and Non-Type 2 Inflammatory Pathways in Pemphigus Vulgaris"],"prefix":"10.1007","volume":"69","author":[{"given":"Gabriela","family":"Soto-Canetti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon R.","family":"Block","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaanvi","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tammy Ehimwenma-Point Du","family":"Jour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Navrazhina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Adalsteinsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Ungar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan","family":"Talia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,11]]},"reference":[{"key":"9181_CR1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01418","volume":"10","author":"D Didona","year":"2019","unstructured":"Didona D, Maglie R, Eming R, Hertl M (2019) Pemphigus: current and future therapeutic strategies. Front Immunol 10:1418. https:\/\/doi.org\/10.3389\/fimmu.2019.01418","journal-title":"Front Immunol"},{"issue":"5","key":"9181_CR2","doi-asserted-by":"publisher","first-page":"758","DOI":"10.4103\/idoj.idoj_740_23","volume":"15","author":"R Choudhary","year":"2024","unstructured":"Choudhary R, Gupta V, Khandpur S (2024) Updates on the Management of Autoimmune Bullous Diseases. Indian Dermatol Online J 15(5):758\u2013769. https:\/\/doi.org\/10.4103\/idoj.idoj_740_23","journal-title":"Indian Dermatol Online J"},{"issue":"1","key":"9181_CR3","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1007\/s10875-011-9597-4","volume":"32","author":"H Zhu","year":"2012","unstructured":"Zhu H, Chen Y, Zhou Y, Wang Y, Zheng J, Pan M (2012) Cognate Th2-B cell interaction is essential for the autoantibody production in pemphigus vulgaris. J Clin Immunol 32(1):114\u2013123. https:\/\/doi.org\/10.1007\/s10875-011-9597-4","journal-title":"J Clin Immunol"},{"issue":"1","key":"9181_CR4","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14605","volume":"34","author":"RM Bakr","year":"2021","unstructured":"Bakr RM, Sayed DS, Abd-Elkader AS, Kamel AA, Badran AY (2021) Does interleukin-33 level correlate with the activity of Pemphigus vulgaris?: a case-control study. Dermatol Ther 34(1):e14605. https:\/\/doi.org\/10.1111\/dth.14605","journal-title":"Dermatol Ther"},{"issue":"3","key":"9181_CR5","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1111\/bjd.13716","volume":"173","author":"A Tirado-S\u00e1nchez","year":"2015","unstructured":"Tirado-S\u00e1nchez A, Bonifaz A, Ponce-Olivera RM (2015) Elevated interleukin-33 and soluble ST2 levels in the sera of patients with pemphigus vulgaris: correlation with clinical and immunological parameters during follow-up. Br J Dermatol 173(3):818\u2013820. https:\/\/doi.org\/10.1111\/bjd.13716","journal-title":"Br J Dermatol"},{"issue":"2","key":"9181_CR6","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.jaci.2007.06.004","volume":"120","author":"YJ Liu","year":"2007","unstructured":"Liu YJ (2007) Thymic stromal lymphopoietin and OX40 ligand pathway in the initiation of dendritic cell-mediated allergic inflammation. J Allergy Clin Immunol 120(2):238\u2013244. https:\/\/doi.org\/10.1016\/j.jaci.2007.06.004. quiz 245\u2013246","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"9181_CR7","doi-asserted-by":"publisher","first-page":"443","DOI":"10.2332\/allergolint.13-OA-0672","volume":"63","author":"N Murakami-Satsutani","year":"2014","unstructured":"Murakami-Satsutani N, Ito T, Nakanishi T et al (2014) IL-33 promotes the induction and maintenance of Th2 immune responses by enhancing the function of OX40 ligand. Allergol Int Off J Jpn Soc Allergol 63(3):443\u2013455. https:\/\/doi.org\/10.2332\/allergolint.13-OA-0672","journal-title":"Allergol Int Off J Jpn Soc Allergol"},{"issue":"7","key":"9181_CR8","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1111\/all.14196","volume":"75","author":"S Toki","year":"2020","unstructured":"Toki S, Goleniewska K, Zhang J et al (2020) TSLP and IL-33 reciprocally promote each other\u2019s lung protein expression and ILC2 receptor expression to enhance innate type-2 airway inflammation. Allergy 75(7):1606\u20131617. https:\/\/doi.org\/10.1111\/all.14196","journal-title":"Allergy"},{"key":"9181_CR9","doi-asserted-by":"publisher","first-page":"17026","DOI":"10.1038\/nrdp.2017.26","volume":"3","author":"M Kasperkiewicz","year":"2017","unstructured":"Kasperkiewicz M, Ellebrecht CT, Takahashi H et al (2017) Pemphigus. Nat Rev Dis Primer 3:17026. https:\/\/doi.org\/10.1038\/nrdp.2017.26","journal-title":"Nat Rev Dis Primer"},{"key":"9181_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1500231","volume":"15","author":"RR Schwartz","year":"2024","unstructured":"Schwartz RR, Seiffert-Sinha K, Sinha AA (2024) Cytokine profiling reveals HLA-linked Th2 and Th17 driven immune activation in pemphigus vulgaris patients and genetically susceptible healthy controls. Front Immunol 15:1500231. https:\/\/doi.org\/10.3389\/fimmu.2024.1500231","journal-title":"Front Immunol"},{"issue":"1","key":"9181_CR11","doi-asserted-by":"publisher","first-page":"635","DOI":"10.4049\/jimmunol.170.1.635","volume":"170","author":"C Veldman","year":"2003","unstructured":"Veldman C, Stauber A, Wassmuth R, Uter W, Schuler G, Hertl M (2003) Dichotomy of autoreactive Th1 and Th2 cell responses to desmoglein 3 in patients with pemphigus vulgaris (PV) and healthy carriers of PV-associated HLA class II alleles. J Immunol 170(1):635\u2013642. https:\/\/doi.org\/10.4049\/jimmunol.170.1.635","journal-title":"J Immunol"},{"issue":"12","key":"9181_CR12","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1111\/j.1600-0625.2005.00367.x","volume":"14","author":"C Sitaru","year":"2005","unstructured":"Sitaru C, Zillikens D (2005) Mechanisms of blister induction by autoantibodies. Exp Dermatol 14(12):861\u2013875. https:\/\/doi.org\/10.1111\/j.1600-0625.2005.00367.x","journal-title":"Exp Dermatol"},{"issue":"6","key":"9181_CR13","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1080\/08820130902943097","volume":"38","author":"A Satyam","year":"2009","unstructured":"Satyam A, Khandpur S, Sharma VK, Sharma A (2009) Involvement of T(H)1\/T(H)2 cytokines in the pathogenesis of autoimmune skin disease-Pemphigus vulgaris. Immunol Invest 38(6):498\u2013509. https:\/\/doi.org\/10.1080\/08820130902943097","journal-title":"Immunol Invest"},{"issue":"5","key":"9181_CR14","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/j.autrev.2019.03.009","volume":"18","author":"EH Kowalski","year":"2019","unstructured":"Kowalski EH, Kneibner D, Kridin K, Amber KT (2019) Serum and blister fluid levels of cytokines and chemokines in pemphigus and bullous pemphigoid. Autoimmun Rev 18(5):526\u2013534. https:\/\/doi.org\/10.1016\/j.autrev.2019.03.009","journal-title":"Autoimmun Rev"},{"issue":"9","key":"9181_CR15","doi-asserted-by":"publisher","DOI":"10.1111\/exd.15173","volume":"33","author":"S You","year":"2024","unstructured":"You S, Ouyang J, Wu Q et al (2024) Comparison of serum cytokines and chemokines levels and clinical significance in patients with pemphigus vulgaris-A retrospective study. Exp Dermatol 33(9):e15173. https:\/\/doi.org\/10.1111\/exd.15173","journal-title":"Exp Dermatol"},{"issue":"4","key":"9181_CR16","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1002\/jvc2.396","volume":"3","author":"T Takegami","year":"2024","unstructured":"Takegami T, Yonekura S, Nomura T, Egawa G, Kabashima K (2024) TARC\/CCL17 reflects the severity of pemphigus (pemphigus vulgaris and pemphigus foliaceus) at the initial presentation. JEADV Clin Pract 3(4):1175\u20131178. https:\/\/doi.org\/10.1002\/jvc2.396","journal-title":"JEADV Clin Pract"},{"issue":"1","key":"9181_CR17","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1007\/s00403-006-0661-5","volume":"298","author":"T Echigo","year":"2006","unstructured":"Echigo T, Hasegawa M, Shimada Y, Inaoki M, Takehara K, Sato S (2006) Both Th1 and Th2 chemokines are elevated in sera of patients with autoimmune blistering diseases. Arch Dermatol Res 298(1):38\u201345. https:\/\/doi.org\/10.1007\/s00403-006-0661-5","journal-title":"Arch Dermatol Res"},{"issue":"10","key":"9181_CR18","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1016\/j.imbio.2015.06.008","volume":"220","author":"R Asothai","year":"2015","unstructured":"Asothai R, Anand V, Das D et al (2015) Distinctive Treg associated CCR4-CCL22 expression profile with altered frequency of Th17\/Treg cell in the immunopathogenesis of Pemphigus Vulgaris. Immunobiology 220(10):1129\u20131135. https:\/\/doi.org\/10.1016\/j.imbio.2015.06.008","journal-title":"Immunobiology"},{"issue":"1","key":"9181_CR19","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1007\/s12026-023-09413-0","volume":"72","author":"D Das","year":"2024","unstructured":"Das D, Arava S, Khandpur S, Santosh KV, Akhtar S, Sharma A (2024) Dominance and improved survivability of human \u03b3\u03b4T17 cell subset aggravates the immunopathogenesis of pemphigus vulgaris. Immunol Res 72(1):72\u201381. https:\/\/doi.org\/10.1007\/s12026-023-09413-0","journal-title":"Immunol Res"},{"issue":"2","key":"9181_CR20","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jid.2023.07.025","volume":"144","author":"D Didona","year":"2024","unstructured":"Didona D, Scarsella L, Hudemann C et al (2024) Type 2 T-Cell Responses against Distinct Epitopes of the Desmoglein 3 Ectodomain in Pemphigus Vulgaris. J Invest Dermatol 144(2):263\u2013272e8. https:\/\/doi.org\/10.1016\/j.jid.2023.07.025","journal-title":"J Invest Dermatol"},{"issue":"4","key":"9181_CR21","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1111\/1346-8138.70077","volume":"53","author":"LYY Yang","year":"2026","unstructured":"Yang LYY, Zuo YG (2026) Updates in Pathogenesis of Pemphigus Vulgaris. J Dermatol 53(4):547\u2013555. https:\/\/doi.org\/10.1111\/1346-8138.70077","journal-title":"J Dermatol"},{"issue":"9","key":"9181_CR22","first-page":"532","volume":"43","author":"D D\u2019Ippolito","year":"2018","unstructured":"D\u2019Ippolito D, Pisano M (2018) Dupilumab (Dupixent): An Interleukin-4 Receptor Antagonist for Atopic Dermatitis. P T Peer-Rev J Formul Manag 43(9):532\u2013535","journal-title":"P T Peer-Rev J Formul Manag"},{"issue":"7","key":"9181_CR23","doi-asserted-by":"publisher","first-page":"2991","DOI":"10.1007\/s12325-024-02810-3","volume":"41","author":"DF Murrell","year":"2024","unstructured":"Murrell DF, Joly P, Werth VP et al (2024) Study Design of a Phase 2\/3 Randomized Controlled Trial of Dupilumab in Adults with Bullous Pemphigoid: LIBERTY-BP ADEPT. Adv Ther 41(7):2991\u20133002. https:\/\/doi.org\/10.1007\/s12325-024-02810-3","journal-title":"Adv Ther"},{"key":"9181_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.825796","volume":"13","author":"S Chen","year":"2022","unstructured":"Chen S, Zhan S, Hua C, Tang Y, Cheng H (2022) A novel combined use of dupilumab for treatment of aggressive refractory pemphigus vulgaris complicated with pulmonary tuberculosis: a case report and the RNA-seq analysis. Front Immunol 13:825796. https:\/\/doi.org\/10.3389\/fimmu.2022.825796","journal-title":"Front Immunol"},{"key":"9181_CR25","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.jdcr.2022.10.035","volume":"31","author":"AY Moore","year":"2023","unstructured":"Moore AY, Hurley K (2023) Dupilumab monotherapy suppresses recalcitrant pemphigus vulgaris. JAAD Case Rep 31:16\u201318. https:\/\/doi.org\/10.1016\/j.jdcr.2022.10.035","journal-title":"JAAD Case Rep"},{"issue":"2","key":"9181_CR26","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1111\/pde.15779","volume":"42","author":"S Yun","year":"2025","unstructured":"Yun S, Jenkins BA, Scollan ME et al (2025) Pemphigus Vulgaris With Esophageal Involvement in an Atopic Child Successfully Treated With Dupilumab. Pediatr Dermatol 42(2):371\u2013375. https:\/\/doi.org\/10.1111\/pde.15779","journal-title":"Pediatr Dermatol"},{"issue":"12","key":"9181_CR27","doi-asserted-by":"publisher","first-page":"2341","DOI":"10.1111\/ijd.17902","volume":"64","author":"F Koroma","year":"2025","unstructured":"Koroma F, Amara S, Lebwohl M (2025) The Efficacy of Dupilumab in Pemphigus Vulgaris. Int J Dermatol 64(12):2341\u20132342. https:\/\/doi.org\/10.1111\/ijd.17902","journal-title":"Int J Dermatol"},{"issue":"3","key":"9181_CR28","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/j.jaad.2014.04.053","volume":"71","author":"KK Yu","year":"2014","unstructured":"Yu KK, Crew AB, Messingham KAN, Fairley JA, Woodley DT (2014) Omalizumab therapy for bullous pemphigoid. J Am Acad Dermatol 71(3):468\u2013474. https:\/\/doi.org\/10.1016\/j.jaad.2014.04.053","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"9181_CR29","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15646","volume":"35","author":"A Ji-Xu","year":"2022","unstructured":"Ji-Xu A, Artounian K, Fung MA, Le ST, Maverakis E (2022) Omalizumab as adjuvant therapy for pemphigus vulgaris. Dermatol Ther 35(8):e15646. https:\/\/doi.org\/10.1111\/dth.15646","journal-title":"Dermatol Ther"},{"issue":"3","key":"9181_CR30","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.clim.2009.11.006","volume":"134","author":"A Nagel","year":"2010","unstructured":"Nagel A, Lang A, Engel D et al (2010) Clinical activity of pemphigus vulgaris relates to IgE autoantibodies against desmoglein 3. Clin Immunol 134(3):320\u2013330. https:\/\/doi.org\/10.1016\/j.clim.2009.11.006","journal-title":"Clin Immunol"},{"issue":"9","key":"9181_CR31","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1001\/jamadermatol.2023.2428","volume":"159","author":"L Zhao","year":"2023","unstructured":"Zhao L, Wang Q, Liang G et al (2023) Evaluation of Dupilumab in Patients With Bullous Pemphigoid. JAMA Dermatol 159(9):953\u2013960. https:\/\/doi.org\/10.1001\/jamadermatol.2023.2428","journal-title":"JAMA Dermatol"},{"key":"9181_CR32","doi-asserted-by":"publisher","unstructured":"Karpoff K, Patel A, Erfe G, Guttman-Yassky E, Lebwohl M Real-World Evidence of Dupilumab\u2019s Efficacy in Reducing Autoantibodies to Bullous Pemphigoid Antigens. Int J Dermatol. n\/a(n\/a). https:\/\/doi.org\/10.1111\/ijd.70460","DOI":"10.1111\/ijd.70460"},{"issue":"4","key":"9181_CR33","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1016\/j.jid.2025.08.039","volume":"146","author":"J Marschall","year":"2026","unstructured":"Marschall J, Schierhofer LIA, Santos AMS et al (2026) Deep Analysis of Desmoglein-3\u2013Reactive CD4\u2009+\u2009T Cells in Pemphigus Vulgaris Reveals a Type 17\/Type 2 T-Cell Signature. J Invest Dermatol 146(4):973\u2013985e6. https:\/\/doi.org\/10.1016\/j.jid.2025.08.039","journal-title":"J Invest Dermatol"},{"key":"9181_CR34","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/7151285","volume":"2017","author":"RP Timoteo","year":"2017","unstructured":"Timoteo RP, da Silva MV, Miguel CB et al (2017) Th1\/Th17-related cytokines and chemokines and their implications in the pathogenesis of pemphigus vulgaris. Mediators Inflamm 2017:7151285. https:\/\/doi.org\/10.1155\/2017\/7151285","journal-title":"Mediators Inflamm"},{"issue":"3","key":"9181_CR35","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.jdermsci.2008.09.008","volume":"53","author":"M Arakawa","year":"2009","unstructured":"Arakawa M, Dainichi T, Yasumoto S, Hashimoto T (2009) Lesional Th17 cells in pemphigus vulgaris and pemphigus foliaceus. J Dermatol Sci 53(3):228\u2013231. https:\/\/doi.org\/10.1016\/j.jdermsci.2008.09.008","journal-title":"J Dermatol Sci"},{"issue":"6","key":"9181_CR36","doi-asserted-by":"publisher","first-page":"2358","DOI":"10.1016\/j.jaci.2020.11.008","volume":"147","author":"J Holstein","year":"2021","unstructured":"Holstein J, Solimani F, Baum C et al (2021) Immunophenotyping in pemphigus reveals a TH17\/TFH17 cell-dominated immune response promoting desmoglein1\/3-specific autoantibody production. J Allergy Clin Immunol 147(6):2358\u20132369. https:\/\/doi.org\/10.1016\/j.jaci.2020.11.008","journal-title":"J Allergy Clin Immunol"},{"key":"9181_CR37","doi-asserted-by":"publisher","first-page":"103128","DOI":"10.1016\/j.jaut.2023.103128","volume":"142","author":"C Xu","year":"2024","unstructured":"Xu C, Zhang T, Wang H et al (2024) Integrative single-cell analysis reveals distinct adaptive immune signatures in the cutaneous lesions of pemphigus. J Autoimmun 142:103128. https:\/\/doi.org\/10.1016\/j.jaut.2023.103128","journal-title":"J Autoimmun"},{"key":"9181_CR38","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02871","volume":"9","author":"WA Rose","year":"2018","unstructured":"Rose WA, Okragly AJ, Hu NN et al (2018) Interleukin-33 contributes toward loss of tolerance by promoting B-cell-activating factor of the tumor-necrosis-factor family (BAFF)-dependent autoantibody production. Front Immunol 9:2871. https:\/\/doi.org\/10.3389\/fimmu.2018.02871","journal-title":"Front Immunol"},{"issue":"4","key":"9181_CR39","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1111\/ijd.16363","volume":"62","author":"E Daneshvar","year":"2023","unstructured":"Daneshvar E, Tavakolpour S, Mahmoudi H et al (2023) Elevated serum level of B-cell activating factor (BAFF) after rituximab therapy in pemphigus vulgaris patients suggests a possible therapeutic efficacy of B-cell depletion therapies combined with anti-BAFF agents. Int J Dermatol 62(4):567\u2013574. https:\/\/doi.org\/10.1111\/ijd.16363","journal-title":"Int J Dermatol"},{"issue":"2","key":"9181_CR40","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1111\/j.1365-2133.2006.07305.x","volume":"155","author":"N Asashima","year":"2006","unstructured":"Asashima N, Fujimoto M, Watanabe R et al (2006) Serum levels of BAFF are increased in bullous pemphigoid but not in pemphigus vulgaris. Br J Dermatol 155(2):330\u2013336. https:\/\/doi.org\/10.1111\/j.1365-2133.2006.07305.x","journal-title":"Br J Dermatol"},{"issue":"8","key":"9181_CR41","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15621","volume":"35","author":"J Ruan","year":"2022","unstructured":"Ruan J, Zhang X, Zheng M (2022) Belimumab for the treatment of pemphigus. Dermatol Ther 35(8):e15621. https:\/\/doi.org\/10.1111\/dth.15621","journal-title":"Dermatol Ther"},{"issue":"1","key":"9181_CR42","doi-asserted-by":"publisher","first-page":"75","DOI":"10.4103\/ijd.ijd_599_24","volume":"71","author":"L Zheng","year":"2026","unstructured":"Zheng L, Si Y, She X, Fang R (2026) Pemphigus Vulgaris Successfully Treated with Belimumab: A Case Report. Indian J Dermatol 71(1):75\u201377. https:\/\/doi.org\/10.4103\/ijd.ijd_599_24","journal-title":"Indian J Dermatol"},{"issue":"3","key":"9181_CR43","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1093\/bjd\/ljaf437","volume":"194","author":"X Peng","year":"2026","unstructured":"Peng X, Ran Y, Wang S et al (2026) Tumour necrosis factor-like weak inducer of apoptosis (TWEAK) is associated with inflammation and disease severity in pemphigus. Br J Dermatol 194(3):540\u2013550. https:\/\/doi.org\/10.1093\/bjd\/ljaf437","journal-title":"Br J Dermatol"},{"issue":"5","key":"9181_CR44","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1093\/bjd\/ljag022","volume":"194","author":"P Zheng","year":"2026","unstructured":"Zheng P, Chen L (2026) Mechanistic and systemic perspectives on tumour necrosis factor-like weak inducer of apoptosis in pemphigus vulgaris. Br J Dermatol 194(5):984\u2013985. https:\/\/doi.org\/10.1093\/bjd\/ljag022","journal-title":"Br J Dermatol"},{"issue":"3","key":"9181_CR45","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/s12079-018-0464-4","volume":"12","author":"SM Pinto","year":"2018","unstructured":"Pinto SM, Subbannayya Y, Rex DaB et al (2018) A network map of IL-33 signaling pathway. J Cell Commun Signal 12(3):615\u2013624. https:\/\/doi.org\/10.1007\/s12079-018-0464-4","journal-title":"J Cell Commun Signal"},{"issue":"Suppl 2","key":"9181_CR46","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1159\/000350363","volume":"161","author":"M Kurokawa","year":"2013","unstructured":"Kurokawa M, Matsukura S, Kawaguchi M et al (2013) Interleukin-33-activated dendritic cells induce the production of thymus and activation-regulated chemokine and macrophage-derived chemokine. Int Arch Allergy Immunol 161(Suppl 2):52\u201357. https:\/\/doi.org\/10.1159\/000350363","journal-title":"Int Arch Allergy Immunol"},{"issue":"6","key":"9181_CR47","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1016\/j.jaip.2022.01.040","volume":"10","author":"R Chan","year":"2022","unstructured":"Chan R, Stewart K, Misirovs R, Lipworth BJ (2022) Targeting downstream type 2 cytokines or upstream epithelial alarmins for severe asthma. J Allergy Clin Immunol Pract 10(6):1497\u20131505. https:\/\/doi.org\/10.1016\/j.jaip.2022.01.040","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"18","key":"9181_CR48","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1056\/NEJMoa2024257","volume":"385","author":"ME Wechsler","year":"2021","unstructured":"Wechsler ME, Ruddy MK, Pavord ID et al (2021) Efficacy and Safety of Itepekimab in Patients with Moderate-to-Severe Asthma. N Engl J Med 385(18):1656\u20131668. https:\/\/doi.org\/10.1056\/NEJMoa2024257","journal-title":"N Engl J Med"},{"key":"9181_CR49","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.cyto.2017.07.022","volume":"99","author":"SH Park","year":"2017","unstructured":"Park SH, Kim MS, Lim HX, Cho D, Kim TS (2017) IL-33-matured dendritic cells promote Th17 cell responses via IL-1\u03b2 and IL-6. Cytokine 99:106\u2013113. https:\/\/doi.org\/10.1016\/j.cyto.2017.07.022","journal-title":"Cytokine"},{"issue":"5","key":"9181_CR50","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.7150\/thno.80483","volume":"13","author":"M Song","year":"2023","unstructured":"Song M, Yang J, Di M et al (2023) Alarmin IL-33 orchestrates antitumoral T cell responses to enhance sensitivity to 5-fluorouracil in colorectal cancer. Theranostics 13(5):1649\u20131668. https:\/\/doi.org\/10.7150\/thno.80483","journal-title":"Theranostics"},{"issue":"11","key":"9181_CR51","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1016\/S2213-2600(21)00167-3","volume":"9","author":"KF Rabe","year":"2021","unstructured":"Rabe KF, Celli BR, Wechsler ME et al (2021) Safety and efficacy of itepekimab in patients with moderate-to-severe COPD: a genetic association study and randomised, double-blind, phase 2a trial. Lancet Respir Med 9(11):1288\u20131298. https:\/\/doi.org\/10.1016\/S2213-2600(21)00167-3","journal-title":"Lancet Respir Med"},{"issue":"8","key":"9181_CR52","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13874","volume":"17","author":"MP Kosloski","year":"2024","unstructured":"Kosloski MP, Guttman-Yassky E, Cork MJ et al (2024) Pharmacokinetics and pharmacodynamics of itepekimab in adults with moderate-to-severe atopic dermatitis: results from two terminated phase II trials. Clin Transl Sci 17(8):e13874. https:\/\/doi.org\/10.1111\/cts.13874","journal-title":"Clin Transl Sci"},{"key":"9181_CR53","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.humpath.2023.03.017","volume":"140","author":"LA Caro-Chang","year":"2023","unstructured":"Caro-Chang LA, Fung MA (2023) The role of eosinophils in the differential diagnosis of inflammatory skin diseases. Hum Pathol 140:101\u2013128. https:\/\/doi.org\/10.1016\/j.humpath.2023.03.017","journal-title":"Hum Pathol"},{"issue":"6","key":"9181_CR54","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/j.abd.2019.02.002","volume":"94","author":"KL Morais","year":"2019","unstructured":"Morais KL, Miyamoto D, Maruta CW, Aoki V (2019) Diagnostic approach of eosinophilic spongiosis. Bras Dermatol 94(6):724\u2013728. https:\/\/doi.org\/10.1016\/j.abd.2019.02.002","journal-title":"Bras Dermatol"},{"issue":"4","key":"9181_CR55","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/j.jaci.2012.07.010","volume":"130","author":"SF Ziegler","year":"2012","unstructured":"Ziegler SF (2012) Thymic stromal lymphopoietin and allergic disease. J Allergy Clin Immunol 130(4):845\u2013852. https:\/\/doi.org\/10.1016\/j.jaci.2012.07.010","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"9181_CR56","doi-asserted-by":"publisher","DOI":"10.1093\/jleuko\/qiae216","volume":"117","author":"PP Domeier","year":"2025","unstructured":"Domeier PP, Ziegler SF (2025) Thymic stromal lymphopoietin signaling in B cells from progenitors to plasma cells. J Leukoc Biol 117(2):qiae216. https:\/\/doi.org\/10.1093\/jleuko\/qiae216","journal-title":"J Leukoc Biol"},{"issue":"5","key":"9181_CR57","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1084\/jem.20150402","volume":"214","author":"L Pattarini","year":"2017","unstructured":"Pattarini L, Trichot C, Bogiatzi S et al (2017) TSLP-activated dendritic cells induce human T follicular helper cell differentiation through OX40-ligand. J Exp Med 214(5):1529\u20131546. https:\/\/doi.org\/10.1084\/jem.20150402","journal-title":"J Exp Med"},{"issue":"9","key":"9181_CR58","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1084\/jem.20051135","volume":"202","author":"T Ito","year":"2005","unstructured":"Ito T, Wang YH, Duramad O et al (2005) TSLP-activated dendritic cells induce an inflammatory T helper type 2 cell response through OX40 ligand. J Exp Med 202(9):1213\u20131223. https:\/\/doi.org\/10.1084\/jem.20051135","journal-title":"J Exp Med"},{"key":"9181_CR59","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.698522","volume":"12","author":"SH Wang","year":"2021","unstructured":"Wang SH, Zuo YG (2021) Thymic stromal lymphopoietin in cutaneous immune-mediated diseases. Front Immunol 12:698522. https:\/\/doi.org\/10.3389\/fimmu.2021.698522","journal-title":"Front Immunol"},{"issue":"8","key":"9181_CR60","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1080\/14728222.2020.1783242","volume":"24","author":"GM Gauvreau","year":"2020","unstructured":"Gauvreau GM, Sehmi R, Ambrose CS, Griffiths JM (2020) Thymic stromal lymphopoietin: its role and potential as a therapeutic target in asthma. Expert Opin Ther Targets 24(8):777\u2013792. https:\/\/doi.org\/10.1080\/14728222.2020.1783242","journal-title":"Expert Opin Ther Targets"},{"key":"9181_CR61","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/4594630","volume":"2020","author":"SZ Li","year":"2020","unstructured":"Li SZ, Jin XX, Ge XL, Zuo YG, Jin HZ (2020) Thymic stromal lymphopoietin is implicated in the pathogenesis of bullous pemphigoid by dendritic cells. J Immunol Res 2020:4594630. https:\/\/doi.org\/10.1155\/2020\/4594630","journal-title":"J Immunol Res"},{"issue":"7","key":"9181_CR62","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1111\/1346-8138.16730","volume":"50","author":"S Okuno","year":"2023","unstructured":"Okuno S, Hashimoto T, Yamazaki Y, Okuzawa M, Satoh T (2023) IL-31 and IL-31 receptor alpha in pemphigus: Contributors to more than just itch? J Dermatol 50(7):927\u2013930. https:\/\/doi.org\/10.1111\/1346-8138.16730","journal-title":"J Dermatol"},{"issue":"10","key":"9181_CR63","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1056\/NEJMoa1704064","volume":"377","author":"J Corren","year":"2017","unstructured":"Corren J, Parnes JR, Wang L et al (2017) Tezepelumab in Adults with Uncontrolled Asthma. N Engl J Med 377(10):936\u2013946. https:\/\/doi.org\/10.1056\/NEJMoa1704064","journal-title":"N Engl J Med"},{"issue":"19","key":"9181_CR64","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1056\/NEJMoa2034975","volume":"384","author":"A Menzies-Gow","year":"2021","unstructured":"Menzies-Gow A, Corren J, Bourdin A et al (2021) Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma. N Engl J Med 384(19):1800\u20131809. https:\/\/doi.org\/10.1056\/NEJMoa2034975","journal-title":"N Engl J Med"},{"issue":"1","key":"9181_CR65","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1164\/rccm.202210-2005OC","volume":"208","author":"J Corren","year":"2023","unstructured":"Corren J, Menzies-Gow A, Chupp G et al (2023) Efficacy of Tezepelumab in Severe, Uncontrolled Asthma: Pooled Analysis of the PATHWAY and NAVIGATOR Clinical Trials. Am J Respir Crit Care Med 208(1):13\u201324. https:\/\/doi.org\/10.1164\/rccm.202210-2005OC","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"9181_CR66","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/j.anai.2021.08.008","volume":"127","author":"TH Pham","year":"2021","unstructured":"Pham TH, Chen C, Colice G, Parnes JR, Griffiths JM, Cook B (2021) Tezepelumab normalizes serum interleukin-5 and \u2013\u200913 levels in patients with severe, uncontrolled asthma. Ann Allergy Asthma Immunol Off Publ Am Coll Allergy Asthma Immunol 127(6):689\u2013691. https:\/\/doi.org\/10.1016\/j.anai.2021.08.008","journal-title":"Ann Allergy Asthma Immunol Off Publ Am Coll Allergy Asthma Immunol"},{"issue":"6","key":"9181_CR67","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1111\/all.15197","volume":"77","author":"J Corren","year":"2022","unstructured":"Corren J, Pham TH, Garcia Gil E et al (2022) Baseline type 2 biomarker levels and response to tezepelumab in severe asthma. Allergy 77(6):1786\u20131796. https:\/\/doi.org\/10.1111\/all.15197","journal-title":"Allergy"},{"issue":"2","key":"9181_CR68","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1093\/abt\/tbae006","volume":"7","author":"X Liu","year":"2024","unstructured":"Liu X, Han J, Wang Q et al (2024) Development of a novel humanized anti-TSLP monoclonal antibody HZ-1127 with anti-allergic diseases and cancer potential. Antib Ther 7(2):123\u2013130. https:\/\/doi.org\/10.1093\/abt\/tbae006","journal-title":"Antib Ther"}],"container-title":["Clinical Reviews in Allergy & Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-026-09181-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12016-026-09181-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-026-09181-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T06:32:25Z","timestamp":1789108345000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12016-026-09181-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,11]]},"references-count":68,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["9181"],"URL":"https:\/\/doi.org\/10.1007\/s12016-026-09181-3","relation":{},"ISSN":["1559-0267"],"issn-type":[{"value":"1559-0267","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,11]]},"assertion":[{"value":"13 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"IRB Approval Status\/Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Author BU is an employee of Mount Sinai and has received research funds (grants paid to the institution) from and\/or is a consultant for the following companies: AbbVie, Arcutis Biotherapeutics, Botanix Pharmaceuticals, Bristol Myers Squibb, Castle Biosciences, Ebla Holdco, Fresenius Kabi, Galderma, Incyte, J&J, Leo Pharma, Lilly, Nektar Therapeutics, Pfizer, Primus Pharmaceuticals, Rapt Therapeutics, Sanofi, Sun Pharma, UCB, Veradermics, and VRG Therapeutics. Author JT is an employee of Mount Sinai and is a consultant and\/or investigator for the following companies: Abbvie, Arcutis Biotherapeutics, Attovia Therapeutics, Biogen, Bristol-Meyers Squibb, Calliditas Therapeutics, Incyte, Intellisphere, Johnson & Johnson, Galderma, LEO Pharma, Navigator Medicines, Novartis, Primus Pharmaceuticals, Priovant Therapeutics, Sanofi, Sanofi Genzyme, Stifel Financial, and UCB. He is a shareholder of Zura Bio and Scinai Immunotherapeutics. All other authors have no conflicts of interest to declare.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"77"}}